Provided by Tiger Trade Technology Pte. Ltd.

Seres Therapeutics

14.63
+0.67004.80%
Volume:26.90K
Turnover:385.61K
Market Cap:132.35M
PE:24.54
High:14.69
Open:14.00
Low:13.78
Close:13.96
52wk High:29.98
52wk Low:6.53
Shares:9.05M
Float Shares:6.46M
Volume Ratio:0.29
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.5963
EPS(LYR):0.0175
ROE:15.95%
ROA:-40.12%
PB:3.03
PE(LYR):835.86

Loading ...

Seres Therapeutics Reports SER-155 Reduces Bloodstream Infections in Stem Cell Transplant Patients

Reuters
·
Jan 06

Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy

GlobeNewswire
·
Jan 06

BUZZ-Seres Group's Hong Kong shares jump after joining stock connect program

Reuters
·
Dec 01, 2025

Seres Therapeutics Reports Positive Q3 2025 Results

TIPRANKS
·
Nov 06, 2025

Seres Therapeutics Q3 2025 Earnings Call Summary and Q&A Highlights: SER-155 Progress and Strategic Partnerships

Earnings Call
·
Nov 06, 2025

Seres (MCRB) Q3 2025 Earnings Call Transcript

Motley Fool Transcribing
·
Nov 06, 2025

Analysts’ Top Healthcare Picks: Seres Therapeutics (MCRB), Neurocrine (NBIX)

TIPRANKS
·
Nov 06, 2025

Seres Therapeutics Q3 net income $8.2 mln, reverses loss

Reuters
·
Nov 05, 2025

Seres Therapeutics Q3 EPS USD 0.94

Reuters
·
Nov 05, 2025

Seres Therapeutics Q3 EPS $0.94 Beats $0.67 Estimate, Sales $351.000K Miss $5.875M Estimate

Benzinga
·
Nov 05, 2025

Seres Therapeutics Inc: Expanding Understanding of Broader Ser-155 Therapeutic Opportunity, Expect Obtaining Initial Efficacy Results in Early 2026

THOMSON REUTERS
·
Nov 05, 2025

Seres Therapeutics Inc - Expects to Fund Operations Through Q2 2026 After Cost Reductions

THOMSON REUTERS
·
Nov 05, 2025

Seres Therapeutics Q3 Net Income USD 8.204 Million

THOMSON REUTERS
·
Nov 05, 2025

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire
·
Nov 05, 2025

Huawei's Chinese EV partner Seres' shares slide in Hong Kong debut amid tech slump

Reuters
·
Nov 05, 2025

Seres Therapeutics Inc expected to post earnings of $1.28 a share - Earnings Preview

Reuters
·
Nov 03, 2025

Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025

GlobeNewswire
·
Oct 30, 2025

Seres Therapeutics Secures $3.6 Million CARB-X Grant to Develop Liquid SER-155 for Infection Prevention

Reuters
·
Oct 29, 2025

Seres Therapeutics Announces Positive Phase 1b Data for SER-155 in Reducing Bloodstream Infections in Allogeneic Stem Cell Transplant Patients, Plans Phase 2 Trial

Reuters
·
Oct 14, 2025

Seres Therapeutics Cuts Costs to Extend Cash Runway

TIPRANKS
·
Oct 04, 2025